CJC 1295 With DAC
Looking for high-purity CJC 1295 With DAC to support your pituitary signaling and long-acting GHRH receptor assays? AU Peptides Store offers premium, HPLC-verified CJC 1295 With DAC for sale with guaranteed $\ge 98\%$ purity, designed specifically for advanced laboratory research into extended plasma half-life kinetics, sustained growth hormone release, and downstream IGF-1 cellular pathways.
CJC-1295 With DAC Pharmacological Overview
CJC-1295 With DAC is a synthetic, 30-amino-acid tetrasubstituted peptide analogue of Growth Hormone Releasing Hormone (GHRH). The addition of the Drug Affinity Complex (DAC) bioconjugate allows the peptide to covalently bind to endogenous serum albumin following administration. This bioconjugation protects the molecule from rapid enzymatic cleavage and renal clearance, extending its active terminal half-life to approximately 6 to 8 days.
CJC-1295 With DAC
The inclusion of the Drug Affinity Complex (DAC) fundamentally alters the pharmacokinetic behavior of CJC-1295 by enabling selective, covalent bonding to circulating albumin molecules. In experimental protocols, this albumin-binding dynamic shields the peptide backbone from rapid dipeptidyl peptidase-IV (DPP-IV) cleavage. As a result, researchers observe a steady, continuous release curve rather than acute plasma spikes, allowing for extended investigation into prolonged somatotroph receptor activation and persistent baseline IGF-1 elevation.
CJC-1295 With DAC Comparative Research Kinetics
When compared directly to non-conjugated GHRH analogues, CJC-1295 With DAC for sale at AU Peptides Store provides superior structural stability for extended longitudinal studies. Laboratory models utilize this long-acting profile to measure continuous cellular repair signaling, systemic nitrogen retention, and ongoing lipolytic pathway engagement over multi-day assay intervals without requiring frequent reconstitution or administration cycles.
